{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:26:46Z","timestamp":1781918806980,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jid.2023.03.1676","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:19:47Z","timestamp":1683307187000},"page":"1625-1628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adalimumab Therapeutic Drug Monitoring Improves Treatment Outcome in Patients with Psoriasis"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4917","authenticated-orcid":false,"given":"Afsaneh","family":"Alavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-6851","authenticated-orcid":false,"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.03.1676_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00575-3","article-title":"Therapeutic drug monitoring in patients with suboptimal response to adalimumab for hidradenitis suppurativa: a retrospective case series","volume":"22","author":"Abdalla","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2023.03.1676_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40257-022-00695-y","article-title":"Author's Reply to Pestana et\u00a0al. Comment on: \"is there a role for therapeutic drug monitoring in patients with hidradenitis suppurativa on tumor necrosis factor-\u03b1 inhibitors?\"","volume":"23","author":"Alavi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2023.03.1676_bib3","article-title":"A\u00a0systematic review on the interest of drug tolerant assay in the monitoring of inflammatory bowel disease [epub ahead of print]","author":"Barrau","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jid.2023.03.1676_bib4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/apt.17170","article-title":"Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the immunogenicity to Second anti-TNF therapy (IMSAT) therapeutic drug monitoring study","volume":"56","author":"Chanchlani","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jid.2023.03.1676_bib5","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A\u00a0comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease","volume":"116","author":"Cheifetz","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jid.2023.03.1676_bib6","first-page":"2075","article-title":"Optimising the therapeutic interval for biologics in patients with psoriasis","volume":"12","author":"Dodero-Anillo","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jid.2023.03.1676_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40259-022-00559-1","article-title":"Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine","volume":"36","author":"Gehin","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.jid.2023.03.1676_bib13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/jdv.14926","article-title":"Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis","volume":"32","author":"Gniadecki","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2023.03.1676_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254548","article-title":"Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease","volume":"16","author":"Kato","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2023.03.1676_bib8","first-page":"1","article-title":"Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: a randomized controlled trial","author":"Pfeiffer-Jensen","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jid.2023.03.1676_bib9","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.jid.2023.01.033","article-title":"Real-world implementation and outcomes of adalimumab therapeutic drug monitoring in psoriasis: a national specialized centre experience","volume":"143","author":"Raharja","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.03.1676_bib15","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/jcm11113011","article-title":"Promising tools to facilitate the implementation of TDM of biologics in clinical practice","volume":"11","author":"Soenen","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jid.2023.03.1676_bib16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: A randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2023.03.1676_bib10","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ajhp\/zxac102","article-title":"National trends in prescription drug expenditures and projections for 2022","volume":"79","author":"Tichy","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jid.2023.03.1676_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","article-title":"Defining the therapeutic range for adalimumab and predicting response in psoriasis: A multicenter prospective observational cohort study","volume":"139","author":"Wilkinson","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.03.1676_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bcp.15535","article-title":"Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database","volume":"89","author":"Zheng","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jid.2023.03.1676_bib17","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/DDDT.S317382","article-title":"An update review of biosimilars of adalimumab in psoriasis - bioequivalence and interchangeability","volume":"15","author":"Zhou","year":"2021","journal-title":"Drug Des Devel Ther"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:31:56Z","timestamp":1758303116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23019760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0022202X23019760"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.03.1676","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab Therapeutic Drug Monitoring Improves Treatment Outcome in Patients with Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.03.1676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}